Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.66 |
| ▸ | DRD3 | P35462 | 11/20 | 0.66 |
| ▸ | DRD4 | P21917 | 5/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477260 | 0.88 | DRD2 (0.58) | DRD2DRD3ADRA1ASMYD2 | |
| SCHEMBL14372243 | 0.88 | DRD3 (0.57) | DRD2DRD3DRD4SMYD2SLC6A4 | |
| SCHEMBL5457389 | 0.84 | DRD2 (0.73) | DRD2DRD3DRD4ADRA1ASLC6A4 | |
| SCHEMBL5470996 | 0.84 | DRD2 (0.57) | DRD2DRD3DRD4ADRA1A | |
| SCHEMBL5468384 | 0.82 | DRD2 (0.62) | DRD2DRD3DRD4SLC6A4 | |
| SCHEMBL5457536 | 0.81 | DRD2 (0.60) | DRD2DRD3 | |
| SCHEMBL5471037 | 0.80 | SMYD2 (0.55) | DRD2DRD3SMYD2 | |
| SCHEMBL5470711 | 0.80 | LMNA (0.48) | DRD2DRD3SMYD2 | |
| SCHEMBL16464148 | 0.79 | DRD3 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL5466569 | 0.78 | MAPT (0.52) | DRD2DRD3DRD4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | DRD2 34/4885DRD3 78/4885DRD4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.